US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.33

-0.0435-0.10%

Post-market: 46.020.6925+1.53%19:30 EDT

Volume:1K

Turnover:49.11K

Market Cap:124.97M

PE:- -

High:46.37

Open:45.39

Low:45.33

Close:45.37

52wk High:48.78

52wk Low:27.68

Shares:2.76M

Float Shares:2.76M

Volume Ratio:0.38

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

LivaNova PLC Lifts Guidance on Record Q2 Results

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Travere Therapeutics to Present at Canaccord Genuity Growth Conference

Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Nyxoah Q2 Revenue Surges on U.S. Growth, but Margins Drop

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

LivaNova is Maintained at Buy by Needham

LivaNova PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

LivaNova Q2 2026 Earnings: Revenue Growth Lifts Guidance

LivaNova Q2 FY26 GAAP Diluted EPS Rises to $1.93; Revenue Increases 10.8% Year over Year to $390.6 Million

UK's LivaNova Q2 Revenue Beats Estimates; Lifts 2026 Outlook

LivaNova Says Cardiopulmonary President Stefano Folli Files Initial Beneficial Ownership Statement

LivaNova Q2 Adjusted EPS USD 1.26 Vs. IBES Estimate USD 1.1

LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate

Benzinga Earnings

LivaNova: Deal Expected to Support Increased Oxygenator Output over Time, Strengthening Co Ability to Satisfy Unmet Customer Demand

THOMSON REUTERS

LivaNova Outlook FY Revenue Growth 8-9%

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/LFSC/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.3275,"timestamp":1789156800000,"preClose":45.371,"halted":0,"volume":1074,"hourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"delay":0,"changeRate":-0.0009587622049327025,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Market Closed","change":-0.0435,"latestTime":"09-11 16:00:00 EDT","open":45.39,"high":46.37,"low":45.3275,"amount":49106.001516000004,"amplitude":0.022977,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":45.371,"sharesOutstanding":2657035,"nav":45.4,"aum":125169389,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"volumeRatio":0.3761557674902608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3761557674902608,"shares":2757035,"dividePrice":0,"high":46.37,"amplitude":0.022977,"preClose":45.371,"low":45.3275,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.3275,"eps":0,"divideRate":0,"volume":1074,"delay":0,"ttmEps":0,"open":45.39,"prevYearClose":36.6147,"prevWeekClose":46.1341,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":46.1466,"twentyDayClose":46.8217,"sixtyDayClose":40.4233},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657570531","title":"LivaNova PLC Lifts Guidance on Record Q2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657570531","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657570531?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:26","pubTimestamp":1785975964,"startTime":"0","endTime":"0","summary":"LivaNova PLC (($LIVN)) has held its Q2 earnings call. Read on for the main highlights of the call. LivaNova PLC’s latest earnings call painted an u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/livanova-plc-lifts-guidance-on-record-q2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/livanova-plc-lifts-guidance-on-record-q2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","PMDE","RGLO","LFSC","LU2065170008.USD","LU2065171311.SGD","VOTE","LIVN","VGFPF","DECU","FEBU","BK4082","GXDW","JOYT","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MRNX","MRNY","IBB","MEDI","IYH","TBXU","RSPH","GDOC","LFSC","PSCH","TECB","BBP","BMED","BK4585","GNMX","FRTY","XLVX","LABU","PINK","NVIB","SYNB","IEIH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657757137","title":"Travere Therapeutics to Present at Canaccord Genuity Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657757137","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657757137?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:48","pubTimestamp":1785966534,"startTime":"0","endTime":"0","summary":"Travere Therapeutics to present at Canaccord Genuity Growth ConferenceTravere Therapeutics management will present at Canaccord Genuity’s 46th Annual Growth Conference on Aug. 11, 2026 at 3 p.m. ET.Ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9MT5yQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","LU1201861249.SGD","LU0072461881.USD","LU1074936037.SGD","LU0170899867.USD","LU0130102774.USD","BK4534","LU0320765646.SGD","LU1366192091.USD","LU0052756011.USD","LU1506573853.SGD","LU0130517989.USD","LU0477156953.USD","LU2236285917.USD","LU1267930227.SGD","LU0203347892.USD","LU0980610538.SGD","LU1244550221.USD","LU0106831901.USD","LU2360032135.SGD","LU2462157665.USD","LU0648001328.SGD","LU0128525689.USD","LU0314106906.USD","TFNS","BK4504","IE00BSNM7G36.USD","LU2125154935.USD","BK4139","LU1244550494.USD","LFSC","LU0162691827.USD","LU2125154778.USD","BK4566","BK4559","LU0203345920.USD","IYF","TVTX","BK4588","LU1162221912.USD","LU2456880835.USD","BK4585","LU1791807156.HKD","BK4207","LU2417539215.USD","LU1244550577.SGD","LU1668664300.SGD","LU0310800965.SGD","FTXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726576","title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726576","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657726576?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:11","pubTimestamp":1785964302,"startTime":"0","endTime":"0","summary":"Guardant Health director Ian T. Clark disposes of common shares worth $2.25 millionGuardant Health director Ian T. Clark reported option exercises on Aug. 4, 2026, acquiring 9,088 common shares at USD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL7mNXxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","GH","BK4588","BK4196","LFSC","LU0889565916.HKD","BK4535","GNMX","GNOM","LU0320765992.SGD","BK4585","EKG","GDOC","HELX","FFOX","LU0109394709.USD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657655575","title":"Akebia Q2 Revenue Falls on Lower Auryxia Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2657655575","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657655575?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:45","pubTimestamp":1785962756,"startTime":"0","endTime":"0","summary":"Akebia Q2 revenue falls on lower Auryxia salesOverviewU.S. kidney disease drugmaker's Q2 revenue fell yr/yr on lower Auryxia salesQ2 net loss and loss per share both beat analyst expectationsVafseo Q2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4196","LFSC","TVTX","BK4588","AKBA","BK4559","DVA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657957897","title":"Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2657957897","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657957897?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:22","pubTimestamp":1785961340,"startTime":"0","endTime":"0","summary":"Sarepta Q2 results beat expectations despite lower sales stemming from Elevidys relabel, unmet Roche milestoneOverviewUS rare disease drugmaker's Q2 revenue fell 34% yr/yr but beat analyst expectation","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","IE00B2B36J28.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4139","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","TVTX","SRPT","LFSC","IE0009355771.USD","BK4585","SRPU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578847","title":"Nyxoah Q2 Revenue Surges on U.S. Growth, but Margins Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578847","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578847?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:16","pubTimestamp":1785961004,"startTime":"0","endTime":"0","summary":"Nyxoah Q2 revenue surges on U.S. growth, but margins dropOverviewBelgium medical device maker's Q2 revenue rose sharply yr/yr on U.S. commercializationGross margin for Q2 declined to 60% from 63% due ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LIVN","BK4585","PODD","LU0728928796.USD","INSP","LU2324357040.USD","BK4588","BK4082","BK4167","LU1261432733.SGD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","LU2065731478.USD","LU1084165304.USD","BK4551","LU1119994496.HKD","LFSC","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520974","title":"Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520974","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520974?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:12","pubTimestamp":1785960723,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals Q2 sales rise, lifts outlookOverviewRare disease drugmaker's Q2 net product sales rose 38% yr/yr to $176 mlnCompany raised 2026 net product sales guidance to $680 mln-$700 mlnQ2 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4149","IE000M9KFDE8.USD","LU0203347892.USD","LU0689626769.HKD","BK4567","TVTX","LU0203345920.USD","LU2065170008.USD","LU2463526074.USD","LU2065171402.SGD","LU0124676726.USD","LU0289961442.SGD","LU0289739343.SGD","CMI","LFSC","ACAD","BK4139","BK4585","MIRM","LU0069063385.USD","LU0511384066.AUD","LU0154245673.USD","LU0472753341.HKD","MADE","LU0154245756.USD","LU0057025933.USD","LU2065171311.SGD","LU2065169927.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521011","title":"LivaNova is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521011","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521011?lang=en_us&edition=fundamental","pubTime":"2026-08-06 01:53","pubTimestamp":1785952380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LIVN/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","BK4082","LU2065170008.USD","LFSC","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540505","title":"LivaNova PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540505","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540505?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:32","pubTimestamp":1785936720,"startTime":"0","endTime":"0","summary":"LivaNova PLC reports results for the quarter ended June 30 - Earnings SummaryLivaNova PLCLIVN.OQreported quarterly adjusted earnings of $1.26 per share for the quarter ended June 30, higher than the s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44223Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065171402.SGD","BK4082","LU2065170008.USD","LIVN","LU2065169927.USD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545831","title":"Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545831?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926714,"startTime":"0","endTime":"0","summary":"Compass Pathways' Q2 loss widens on commercial readiness activity costsOverviewUK mental health biotech's Q2 operating income missed analyst estimatesNet loss widened yr/yr, mainly due to non-cash war","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","LFSC","LU1880407215.USD","LU0266013472.USD","LU1196032939.SGD","LU0310799852.SGD","LU2237443978.SGD","BMY","LU0321505868.SGD","LU0432979614.USD","LU0096364046.USD","LU2596442595.SGD","LU1057294990.SGD","LU1983299246.USD","BK4007","CMPS","LU1585245621.USD","LU2125154935.USD","SG9999001176.USD","LU0203345920.USD","LU2065170008.USD","SGXZ57979304.SGD","LU0575583348.USD","LU0211326839.USD","LIVN","LU1291159041.SGD","LU2065171311.SGD","LU0985481810.HKD","LU0496365809.HKD","LU0997586432.USD","LU2089284900.SGD","PSIL","IHE","LU0306807586.USD","LU2279689827.SGD","ACAD","LU0526926950.USD","LU1273509221.SGD","LU1863844749.USD","FTXH","LU1989772923.USD","LU1153585028.USD","LU1718418525.SGD","LU1670710588.SGD","LU2539964713.USD","LU0757432116.USD","LU1481600234.SGD","03165","LU1046234339.USD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543991","title":"United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543991","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543991?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:38","pubTimestamp":1785926324,"startTime":"0","endTime":"0","summary":"United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weaknessOverviewRare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectationsQ2 net income rose 8% yr/yr; diluted E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","UTHR","TVTX","BK4532","LU1699723380.USD","KRYS","LU1571399168.USD","HELX","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548787","title":"LivaNova Q2 2026 Earnings: Revenue Growth Lifts Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548787","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548787?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:17","pubTimestamp":1785925061,"startTime":"0","endTime":"0","summary":"LivaNova’s Q2 2026 revenue rose 10.8% to $390.6 million, while GAAP diluted EPS increased to $1.93 from $0.50 and adjusted diluted EPS reached $1.26. Cardiopulmonary and Neuromodulation each posted double-digit reported growth. The company raised constant-currency revenue growth guidance to 8%-9% and adjusted EPS guidance to $4.30-$4.40, but reduced adjusted free cash flow guidance to $140-$160 million. A $95.4 million discrete tax benefit materially boosted GAAP net income, while adjusted operating margin improved to 23.2% from 21.9%.","market":"sg","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262077133-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICOW","LIVN","SCOW","BK4585","QFRD","ABLS","FQAL","COWZ","SPHQ","LU2065169927.USD","CALF","ABFL","TPFC","COWG","LFSC","MOTG","QLTY","LGCF","CAFG","BK4082","BK4588","LU2065171402.SGD","NQLT","LU2065171311.SGD","DFNV","LU2065170008.USD","PKW","DSMC","LCOW","ABLG","DIVB","QUAL","SYLD","MCOW","SFLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548533","title":"LivaNova Q2 FY26 GAAP Diluted EPS Rises to $1.93; Revenue Increases 10.8% Year over Year to $390.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548533","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548533?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:13","pubTimestamp":1785924796,"startTime":"0","endTime":"0","summary":"LivaNova Q2 FY26 GAAP diluted EPS rises to $1.93; revenue increases 10.8% year over year to $390.6 millionLivaNova posted Q2 revenue of $390.6 million, up 10.8% from a year earlier; U.S. GAAP diluted ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLyk5Bh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIVN","IE00B4R5TH58.HKD","GB00BDT5M118.USD","LU0957791311.USD","IE0002141913.USD","HRTS","BK4534","LU0011850046.USD","FMED","LU2125909593.SGD","LU0640476718.USD","LU2065169927.USD","LU1989771016.USD","LU0882574055.USD","LU2764263039.SGD","LU2125909247.SGD","IE00BQXX3C00.GBP","LU1988902786.USD","LU1670628061.USD","LU2092937221.SGD","LU0528227936.USD","IE00BJJMRZ35.SGD","BK4535","LU2764262908.HKD","LU0208291251.USD","TMO","LU2211815571.USD","LFSC","LU1923622291.USD","LU1854103824.USD","LU0114720955.EUR","LU1153585028.USD","LU2089984988.USD","LU1815333072.USD","LU2357305700.SGD","LU1720051017.SGD","LU2298321311.HKD","LU0061474960.USD","LU0316494557.USD","IE00B19Z9505.USD","LU2112291526.USD","LU0070302665.USD","TMED","LU0234572021.USD","LU1623119135.USD","IE0034235188.USD","GNMX","LU2764263203.CNY","IE00BKPKM429.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657654837","title":"UK's LivaNova Q2 Revenue Beats Estimates; Lifts 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657654837","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657654837?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:11","pubTimestamp":1785924675,"startTime":"0","endTime":"0","summary":"UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlookOverviewUK medical technology firm's Q2 revenue grew 10.8%, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MADE","LU0114720955.EUR","BK4581","LU0566484027.USD","LU0203347892.USD","LU2468319806.SGD","CLPT","IE000M9KFDE8.USD","LU0096362180.USD","HRTS","IE00BJT1NW94.SGD","LU1815333072.USD","IE00BKPKM429.USD","LU0320765489.SGD","BK4585","LU1559883803.SGD","LU2041044095.USD","LU0342679015.USD","LU0266013472.USD","IE00B1BXHZ80.USD","LU0061474960.USD","LU1791710400.SGD","LU1803068623.USD","LU2360108059.USD","LU2125909916.SGD","ITGR","LFSC","LIVN","LU0528227936.USD","IE00BQXX3F31.USD","LU0124676726.USD","LU0345770993.USD","IE0002141913.USD","LU1169589451.USD","IE00B4R5TH58.HKD","IE0034235188.USD","BK4082","LU1064131342.USD","CMI","LU2211815571.USD","TMED","LU2463526074.USD","LU2720916845.USD","IE00B19Z8X17.USD","LU1815336091.USD","LU0203345920.USD","FMED","GNMX","TMO","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657751001","title":"LivaNova Says Cardiopulmonary President Stefano Folli Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657751001","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657751001?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:07","pubTimestamp":1785924478,"startTime":"0","endTime":"0","summary":"LivaNova says Cardiopulmonary President Stefano Folli files initial beneficial ownership statementLivaNova filed an initial ownership report for Stefano Folli, president of cardiopulmonary, showing 6,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL57w5XY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065171402.SGD","BK4082","LU2065170008.USD","LIVN","LU2065169927.USD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657104155","title":"LivaNova Q2 Adjusted EPS USD 1.26 Vs. IBES Estimate USD 1.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657104155","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657104155?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:01","pubTimestamp":1785924061,"startTime":"0","endTime":"0","summary":"BRIEF-LivaNova Q2 Adjusted EPS USD 1.26 Vs. IBES Estimate USD 1.1Aug 05  - LivaNova Q2 EPS USD 1.93.Q2 revenue USD 390.6 million vs. IBES estimate USD 380.8 millionoutlook FY adjusted EPS USD 4.3-4.4 vs. IBES estimate USD 4.25outlook FY revenue growth 8-9%outlook FY adjusted free cash flow USD 140-160 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX8HZ676:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU2065170008.USD","LU2065171402.SGD","LIVN","BK4082","LU2065171311.SGD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510969","title":"LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510969","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510969?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:00","pubTimestamp":1785924054,"startTime":"0","endTime":"0","summary":"LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.10 by 14.55 percent. This is a 20 percent increase over earnings of $1.05 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60939804/livanova-q2-adj-eps-1-26-beats-1-10-estimate-sales-390-600m-beat-380-758m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LU2065169927.USD","LIVN","LU2065171311.SGD","LFSC","LU2065170008.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657881548","title":"LivaNova: Deal Expected to Support Increased Oxygenator Output over Time, Strengthening Co Ability to Satisfy Unmet Customer Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657881548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657881548?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:00","pubTimestamp":1785924001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX8HZ676:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIVN","LU1548497426.USD","LU2360108059.USD","IE00B19Z8X17.USD","IE0002141913.USD","HRTS","LU0011850046.USD","FMED","LU1791710582.SGD","LU2065169927.USD","LU0345770308.USD","LU1923621640.USD","LU1988902786.USD","LU1670628061.USD","LU0528227936.USD","LU2764262908.HKD","IE00B1BXHZ80.USD","LU0208291251.USD","IE00B19Z8W00.USD","LU0432979614.USD","LU1291159041.SGD","LU1023059063.AUD","LU1633808545.USD","LFSC","LU1803068623.USD","LU1983299246.USD","LU2125910336.SGD","BK4581","LU2211815571.USD","LU2264538146.SGD","LU2468319806.SGD","LU0114720955.EUR","LU1153585028.USD","LU2089984988.USD","LU2357305700.SGD","LU0342679015.USD","LU2211814178.USD","TMO","LU2298321311.HKD","LU0316494557.USD","IE00B19Z9505.USD","LU0070302665.USD","LU1064131342.USD","TMED","LU0096362180.USD","LU1712237335.SGD","GNMX","BK4533","LU2125909759.SGD","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510990","title":"LivaNova Outlook FY Revenue Growth 8-9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510990?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:00","pubTimestamp":1785924001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX8HZ676:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LU2065171402.SGD","LFSC","LU2065171311.SGD","LIVN","BK4082","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}